The expression of CDK12 was lower in prostate cancer samples compared to normal prostate tissue, and CDK12 levels were further significantly lower in metastatic patients than in early‐stage patients (Figure 1C), suggestive of its tumour suppressive role in prostate cancer progression. This evidence concerns the gene CDK12 and prostate carcinoma.